Hungarian pharmaceutical company Gedeon Richter Nyrt more than quadrupled its net income in 2Q10 due to higher sales in the US, receipt of milestone payments from partners and depreciation of the forint.
In the 2nd quarter of 2010, the net profit of the American pharmaceutical company Allergan increased by 36% and amounted to 240 million US dollars. Pharmaceutical sales increased 10%, driven in part by higher sales of Botox anti-wrinkle product. A drug recently approved in the UK to prevent chronic migraines is up 7% to $361 million. The company
In the first quarter of fiscal year 2010 ending March 2011, net income of the Japanese pharmaceutical company Astellas decreased by 10% to 39.5 billion yen (455 million US dollars) due to the appreciation of the yen and the introduction of generic drugs Prograf and Harnal .
British pharmaceutical company Shire has made an offer to acquire Belgian pharmaceutical company Movetis for 428 million euros (565 million US dollars). Movetis specializes in the development and production of medicines for the treatment of gastrointestinal diseases.
In the II quarter of 2010, the net profit of the American pharmaceutical company grew by 9% and amounted to 2.47 billion US dollars against 2.26 billion dollars a year earlier. At the same time, earnings per share decreased by 9% to $0.31 compared to $0.34 in the second quarter of 2009.
Belgian pharmaceutical company UCB beat analysts’ forecasts in 1H 2010 with sales of new medicines offsetting losses from generic competition for blockbusters.
US pharmaceutical company Eli Lilly, Swiss Novartis and Danish Novo Nordisk are potential bidders to acquire Danish biotechnology company Ascendis Pharma, according to an informed source.
French pharmaceutical company Sanofi-Aventis SA may initiate a hostile takeover of US biotech company Genzyme Corp. if the management of the latter refuses the acquisition offer, Citgroup Inc. analysts believe. Mark Dainty and Yaron Werber.
On July 26, the Japanese company Daiichi Sankyo Co. Ltd.” announced that the US Food and Drug Administration (FDA) has approved its combination drug Tribenzor™ (olmesartan + amlodipine + hydrochlorothiazide) for the treatment of hypertension in patients whose blood pressure is unresponsive to other combination antihypertensive drugs. means. Daiichi Sankyo notes that Tribenzor simplifies dosing regimens and also
In the II quarter of 2010, the net profit of the American pharmaceutical company Merck & Co. decreased by 52% due to increased costs, in particular administrative and restructuring, as well as a sharp decrease in profits from partnerships.